Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 3/20 | 0.55 |
| ▸ | ITGAV | P06756 | 3/20 | 0.55 |
| ▸ | MC4R | P32245 | 5/20 | 0.47 |
| ▸ | MC5R | P33032 | 5/20 | 0.47 |
| ▸ | MC3R | P41968 | 5/20 | 0.47 |
| ▸ | MC1R | Q01726 | 5/20 | 0.47 |
| ▸ | CTSG | P08311 | 2/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.45 |
| ▸ | ALB | P02768 | 1/20 | 0.45 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.44 |
| ▸ | TSLP | Q969D9 | 5/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13748443 | 1.00 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13870381 | 1.00 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13748431 | 1.00 | ITGB3 (0.56) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL14324942 | 0.97 | ITGB3 (0.53) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL12353644 | 0.96 | ITGB3 (0.51) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL12353684 | 0.95 | ITGB3 (0.50) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL12462751 | 0.95 | ITGB3 (0.49) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13061299 | 0.95 | ITGB3 (0.49) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL20809940 | 0.95 | ITGB3 (0.49) | ITGB3ITGAVMC4RMC5RMC3R | |
| SCHEMBL13887996 | 0.95 | ITGB3 (0.49) | ITGB3ITGAVMC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233638-A1 | RADIOPHARMACEUTICAL IMAGING METHOD OF ADENOMYOSIS | SERAC HEALTHCARE LTD (GB) | 2025-11-13 | — | — | WO | claimed |
| US-20250186633-A1 | METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS | SERAC HEALTHCARE LTD (GB) | 2025-06-12 | — | — | US | claimed |
| EP-4486396-A1 | METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS | Serac Healthcare Ltd (GB) | 2025-01-08 | — | — | EP | claimed |
| CN-118785926-A | Imaging integrin expression and intrauterine method for imaging a site of endometriosis | 赛瑞科医疗有限公司 | 2024-10-15 | — | — | CN | claimed |
| WO-2023239953-A2 | IMAGING OF MATRIX METALLOPROTEINASE INHIBITORS | MICROVIDE, LLC (US) | 2023-12-14 | — | — | WO | claimed |
| WO-2023166305-A1 | METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS | SERAC HEALTHCARE LTD (GB) | 2023-09-07 | — | — | WO | claimed |
| US-11723991-B2 | Radiopharmaceutical compositions | SERAC HEALTHCARE LIMITED (GB) | 2023-08-15 | — | — | US | claimed |
| EP-3129065-B1 | TARGETED DRUG DELIVERY THROUGH AFFINITY BASED LINKERS | AKAMARA THERAPEUTICS INC (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12605447-B2 | Stable formulations for radionuclide complexes | ITM SOLUCIN GMBH (DE) | 2026-04-21 | — | — | US | disclosed |
| EP-4168492-B1 | NEAR-INFRARED CYANINE DYES AND CONJUGATES THEREOF | BRACCO IMAGING SPA (IT) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025233638-A1 | RADIOPHARMACEUTICAL IMAGING METHOD OF ADENOMYOSIS | SERAC HEALTHCARE LTD (GB) | 2025-11-13 | — | — | WO | disclosed |
| WO-2025233638-A1 | RADIOPHARMACEUTICAL IMAGING METHOD OF ADENOMYOSIS | SERAC HEALTHCARE LTD (GB) | 2025-11-13 | — | — | WO | disclosed |
| US-20250186633-A1 | METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS | SERAC HEALTHCARE LTD (GB) | 2025-06-12 | — | — | US | disclosed |
| WO-2022129336-A1 | PH RESPONSIVE CYANINE DYES AND CONJUGATES THEREOF | BRACCO IMAGING SPA (IT) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022112323-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | ITM SOLUCIN GMBH (DE) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022111800-A1 | STABLE FORMULATIONS FOR RADIONUCLIDE COMPLEXES | ITM SOLUCIN GMBH (DE) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022096673-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022096103-A1 | COMBINATION OF PARA-AMINOHIPPURIC ACID (PAH) AND RADIOLABELED COMPLEXES FOR TREATING CANCER | ITM Isotopen Technologien München AG (DE) | 2022-05-12 | — | — | WO | disclosed |
| EP-3965751-A1 | PARA-AMINOHIPPURIC ACID (PAH) AS A RENAL PROTECTIVE SUBSTANCE | ITM Isotope Technologies Munich SE (DE) | 2022-03-16 | — | — | EP | disclosed |
| CN-114126654-A | Para-aminohippuric acid (PAH) as a kidney protective substance | 同位素技术慕尼黑有限公司 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605447-B2 | Stable formulations for radionuclide complexes | EPOR, CD47, PRCP | ITGB3 1415/4885ITGAV 861/4885MC4R 156/4885 |
| US-11723991-B2 | Radiopharmaceutical compositions | TYMP, KIT, CHEK1 | ITGB3 2816/4885ITGAV 3650/4885MC4R 576/4885 |
| US-20250186633-A1 | METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS | ITGB3, ITGB5, ITGAV | ITGB3 1/4885ITGAV 3/4885MC4R 1473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.